Amedisys Reports Fourth Quarter and Year End 2021 Financial Results; Issues 2022 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Amedisys Reports Fourth Quarter and Year End 2021 Financial Results; Issues 2022 Guidance

Amedisys (AMED) Reports In-Line Q4 EPS

February 23, 2022 4:09 PM EST

Amedisys (NASDAQ: AMED) reported Q4 EPS of $1.18, in-line with the analyst estimate of $1.18. Revenue for the quarter came in at $559.3 million versus the consensus estimate of $555.2 million.

GUIDANCE:

Amedisys sees FY2022 EPS of $5.23-$5.45, versus the consensus of $5.84. Amedisys sees... More